Browse the evidence

SGLT2 inhibitors improve heart failure outcomes through mechanisms independent of glucose lowering, including natriuresis, osmotic diuresis, reduced plasma volume, and improved myocardial energetics via ketone utilization.

SGLT2 inhibitors help the heart by making it work more efficiently. They help remove excess fluid and sodium, reducing strain on the heart, and shift the heart's fuel source to ketones, which are more energy-efficient. This happens regardless of blood sugar levels.

Genetic variants associated with HbA1c levels are linked to an increased risk of coronary artery disease, although this association is attenuated when adjusting for other cardiovascular risk factors.

Higher HbA1c levels are associated with a higher risk of heart disease. While this link is strong, it may be partly explained by other risk factors like cholesterol and weight. Monitoring HbA1c is important for overall cardiovascular health.

Genetic variants associated with fasting glucose (FG) levels do not show a significant independent association with coronary artery disease risk in this Mendelian randomization analysis.

While fasting glucose is a standard test, this genetic study suggests it may not be the primary driver of heart disease risk compared to overall diabetes status or HbA1c. However, maintaining healthy glucose levels is still important.

Post-obese individuals who have successfully lost weight exhibit significantly lower plasma leptin concentrations and lower rates of fat oxidation (higher respiratory quotient) compared to never-obese controls matched for body mass index and body fat percentage.

If you have lost weight and maintained it, your body may still be biologically primed to regain it through lower fat burning and lower leptin levels, even if you look healthy. This is a common biological adaptation, not a failure. To counter this, focus on strategies that increase fat oxidation, such as regular exercise and potentially adjusting fat intake, as suggested by the authors.

Genetic variability in the GLP1R gene can lead to non-response to GLP-1 receptor agonists in some patients with T2DM and obesity.

Some patients with T2DM and obesity do not respond well to GLP-1 receptor agonists due to genetic factors. If you are not seeing results, genetic variability in the GLP-1 receptor might be a cause. Discuss this with your healthcare provider to explore other treatment options or lifestyle interventions.

GLP-1 receptor agonists delay gastric emptying and increase the risk of pulmonary aspiration during general anesthesia, necessitating specific peri-operative management strategies.

If you take a GLP-1 drug (like Ozempic, Wegovy, or Trulicity) and have surgery, tell your anesthesiologist. You likely need to stop the drug for a specific time before surgery (often 3 half-lives, e.g., 1 week for weekly drugs) to prevent stomach contents from entering your lungs while asleep. Do not assume standard fasting rules apply; your stomach may still be full even if you haven't eaten for 12 hours.

Semaglutide improves insulin sensitivity and glucose uptake in skeletal muscle and adipose tissue by activating the PI3K/AKT and AMPK/SIRT1 pathways, leading to GLUT4 translocation, independent of direct insulin action in some contexts.

Semaglutide helps your body use insulin better by activating specific cellular pathways (AMPK/SIRT1) that move glucose into muscles and fat cells. This reduces insulin resistance, a key factor in type 2 diabetes and obesity.

Weight loss-induced metabolic adaptation is defined as a decrease in thermogenesis greater than predicted by changes in body weight and composition, primarily driven by enhanced energy efficiency (e.g., reduced ATP synthesis oxygen need) and neuroendocrine shifts rather than just organ size reduction.

If you are losing weight and hitting a plateau, recognize that your body is likely adapting by becoming more energy-efficient (burning fewer calories for the same tasks) due to hormonal changes and reduced sympathetic tone. This is a normal survival mechanism, not a sign that your diet is failing. To overcome this, you may need to adjust your caloric deficit or increase physical activity, understanding that the rate of loss will naturally slow down.

Liraglutide attenuates nicotine-induced dopamine release in the nucleus accumbens (NAc), potentially reducing the addictive properties of nicotine while maintaining weight loss benefits.

GLP-1 drugs might reduce the 'high' or addictive feeling associated with nicotine, which could make it easier for smokers to quit or use nicotine-based therapies without the usual addiction risks.

Inhibition of the p38 MAPK pathway in white adipose tissue promotes the reprogramming of white adipocytes to beige adipocytes, leading to resistance against diet-induced obesity.

Research suggests that targeting specific signaling pathways like p38 MAPK could potentially help convert energy-storing white fat into energy-burning beige fat, offering a potential future therapeutic strategy for obesity.

Promoting adipogenesis (the creation of new, functional adipocytes) through therapeutic agents can improve lipid storage capacity and prevent the transition from MHO to MUO by avoiding adipocyte dysfunction, hypoxia, and inflammation.

Current lifestyle interventions do not directly target adipogenesis. However, maintaining a healthy weight and avoiding excessive fat accumulation may help preserve adipocyte function. Future therapies may target transcription factors like PPAR-γ to promote healthy fat storage.

GLP-1 receptor agonists (semaglutide, tirzepatide) can cause excessive appetite suppression leading to restrictive eating behaviors, severe food aversion, dehydration, and acute kidney injury when used without intensive clinical monitoring.

If you are taking GLP-1 agonists (like Ozempic or Mounjaro), do not use them without regular medical supervision. Watch for signs of extreme food aversion, dehydration, or rapid weight loss. If you experience severe side effects like kidney issues or inability to eat, contact your doctor immediately. These drugs are powerful and require monitoring, especially if you have a history of eating disorders or have had bariatric surgery.

Individuals with the FADS haplotype D (high-efficiency LC-PUFA biosynthesis) face increased susceptibility to severe COVID-19 when consuming a modern diet high in omega-6 fatty acids, due to the resulting proinflammatory state and cytokine storm.

If you have a family history of high inflammation or belong to a group with higher prevalence of FADS haplotype D (often correlated with African or Hispanic ancestry), prioritize balancing your fatty acid intake. Reduce oils high in omega-6 (corn, soybean, sunflower) and increase omega-3 sources (fish, flax, walnuts) to lower the risk of severe inflammatory responses to infections like COVID-19.

High intake of omega-6 fatty acids and fructose, combined with obesity, creates a chronic low-grade inflammatory state that increases susceptibility to and severity of COVID-19.

To reduce the risk of severe illness from respiratory infections, focus on reducing ultra-processed foods, sugary drinks, and seed oils. Prioritize whole foods, fruits, vegetables, and healthy fats to lower chronic inflammation, which is a key driver of disease severity.

GIP (Glucose-dependent Insulinotropic Polypeptide) promotes fat storage and has unfavorable vascular effects, contrasting with the protective effects of GLP-1.

High-GI foods trigger GIP, which may promote fat storage and inflammation. Avoiding high-GI foods helps minimize GIP release, potentially aiding in weight management and reducing cardiovascular risk factors associated with GIP, such as hepatic steatosis and atherosclerosis.

Environmental cold exposure and specific bioactive compounds (e.g., resveratrol, menthol) induce the browning of white adipose tissue (WAT) and activation of brown adipose tissue (BAT), thereby increasing energy expenditure and improving metabolic health.

You can potentially boost your metabolism by exposing yourself to cold or consuming specific compounds like resveratrol or menthol. These actions encourage your body to convert energy-storing white fat into energy-burning brown or beige fat. While cold exposure is effective, it may be uncomfortable, so exploring dietary sources of these compounds or exercise-induced browning might be more sustainable alternatives for long-term metabolic health.

Obesity and aging are associated with the 'whitening' of brown adipose tissue, characterized by lipid accumulation, loss of mitochondria, and impaired thermogenesis, which contributes to metabolic dysfunction.

As you age or gain weight, your body's ability to burn fat as heat (via brown fat) naturally declines, contributing to further weight gain and metabolic issues. This process is called 'whitening.' While you cannot reverse aging, you can potentially slow this decline by maintaining physical activity and exposing yourself to cold, which may help preserve your brown fat function and metabolic health.

Aging blunts the ability for serial sarcomerogenesis (addition of new sarcomeres in series), leading to shortened fascicle length and impaired muscle mechanical function, primarily due to age-related impairments in mechanotransduction pathways like mTOR, IGF-1, and SRF signaling.

For older adults, maintaining or improving muscle function may require specific interventions that promote muscle lengthening, such as eccentric resistance training or chronic stretching. While muscle mass loss is common, the shortening of muscle fascicles (due to loss of serial sarcomeres) contributes significantly to stiffness and reduced power. Targeted training that emphasizes the lengthening phase of movements may help mitigate these age-related architectural changes, though the response may be slower or smaller than in younger individuals.

Skeletal muscle releases myokines (such as Irisin and Myostatin) during exercise, which mediate interorgan crosstalk to improve metabolic health, regulate adipose tissue, and protect against cardiovascular disease.

Understand that exercise is a systemic therapy. When you move, your muscles release signals that improve the health of your heart, brain, and fat tissue, not just the muscles themselves.

Tirzepatide (TRZD) may increase the risk of cancer progression, specifically pancreatic and medullary thyroid cancer (MTC), through GLP-1R/GIPR-mediated activation of oncogenic pathways (PI3K/Akt/mTOR, Ras-Raf-ERK) and calcitonin release, particularly in patients with prior pancreatitis or family history of MTC.

If you have a personal or family history of Medullary Thyroid Cancer (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2), you should not use Tirzepatide. If you have a history of pancreatitis, use with caution and monitor for symptoms. For other diabetic patients, the long-term cancer risk is currently unknown, but the drug is approved for weight loss and glucose control. Discuss your specific cancer history with your provider before starting.

Tirzepatide (TRZD) and other GLP-1R/GIPR agonists may exhibit anti-cancer properties by sensitizing cancer cells to chemotherapy, inducing apoptosis, and inhibiting proliferation via pathways like PI3K/Akt/mTOR and AMPK, particularly in pancreatic, breast, and colorectal cancers.

Current research shows that drugs like Liraglutide and Exenatide can kill cancer cells or make chemo work better in lab mice. However, there is no proof yet that Tirzepatide does this in humans. Do not use these drugs as a cancer treatment outside of clinical trials.

High-dose omega-3 PUFA supplementation (1-4 g/d) increases the risk of new-onset atrial fibrillation, particularly in elderly patients or those with prior myocardial infarction, likely by prolonging action potential duration via Piezo1 channel modulation.

If you are taking high-dose omega-3 supplements (1-4 grams daily), especially if you are older or have had a heart attack, be aware that this may increase your risk of developing atrial fibrillation (an irregular heartbeat). Consult your doctor before maintaining high doses, as the benefits for inflammation may be offset by this specific cardiac risk.

Bariatric surgery (Roux-en-Y gastric bypass and sleeve gastrectomy) causes a significant decrease in fecal straight short-chain fatty acids (SCFAs), including acetate, propionate, butyrate, and valerate, likely due to altered dietary intake and microbiota fermentation.

If you have had bariatric surgery, expect your gut bacteria to produce fewer beneficial fatty acids (SCFAs) like butyrate. This is a normal physiological change due to the surgery and dietary shifts. To support your gut health, focus on the recommended post-surgical diet, which emphasizes protein and gradually reintroduces fiber-rich foods as tolerated, under the guidance of your healthcare team.

Peri-operative use of GLP-1 receptor agonists delays gastric emptying, increasing the risk of retained gastric contents and pulmonary aspiration during anesthesia, particularly in patients without diabetes or those recently initiating therapy.

If you take GLP-1 medications (like Ozempic or Wegovy) before surgery, tell your anesthesiologist immediately. These drugs slow stomach emptying, which can cause dangerous aspiration during anesthesia. You may need to fast longer or follow a clear-liquid diet for 24 hours before your procedure, even if it is elective. Do not assume standard fasting rules apply.